Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.28 is 540% above its 1-year average of 0.04, near the high end of its 1-year range (-0.15–0.28).
As of the fiscal period ended Tuesday, June 30, 2026. 326.69% above its 12-month average of 0.07.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.28.
DEBT TO EQUITY RATIO
0.28
DEBT TO EQUITY RATIO AVG TTM
0.07
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+326.69%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 716 covered companies
CURRENT VS SECTOR MEDIAN
+158.97%
vs the sector median at left
BlossomHill Therapeutics, Inc.
Market Cap
$531.60M
Debt to Equity Ratio
0.28
TTM Avg
0.07
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.12M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.23
5Y Avg
0.43
Market Cap
$533.91M
Debt to Equity Ratio
N/A
TTM Avg
0.76
3Y Avg
0.54
5Y Avg
0.54
Market Cap
$538.40M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.05
Market Cap
$538.42M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$539.52M
Debt to Equity Ratio
0.01
TTM Avg
0.04
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$523.90M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$523.89M
Debt to Equity Ratio
0.00
TTM Avg
0.04
3Y Avg
0.02
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $531.60M | 0.28 | 0.07 | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 0.02 | 0.01 | 0.23 | 0.43 |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | 0.11 | 0.09 | 0.09 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $533.91M | N/A | 0.76 | 0.54 | 0.54 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $538.40M | 0.00 | 0.01 | 0.01 | 0.05 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $538.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Shattuck Labs, Inc. (STTK)vs › | $539.52M | 0.01 | 0.04 | 0.03 | 0.02 |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Immix Biopharma, Inc. (IMMX)vs › | $523.89M | 0.00 | 0.04 | 0.02 | 0.02 |
| Altimmune, Inc. (ALT)vs › | $516.33M | 0.08 | 0.09 | 0.04 | 0.03 |
Debt/Equity
0.28
Current Ratio
5.42
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.28 |
| 2026-03-31 | -0.15 |
| 2025-03-31 | 0.00 |
